Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51

Wei Lv, Brian Budke, Michal Pawlowski, Philip P. Connell, Alan P. Kozikowski

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


RAD51 is the central protein in homologous recombination (HR) DNA repair and represents a therapeutic target in oncology. Herein we report a novel class of RAD51 inhibitors that were identified by high throughput screening. In contrast to many previously reported RAD51 inhibitors, our lead compound 1 is capable of blocking RAD51-mediated D-loop formation (IC50 21.3 ± 7.8 μM) at concentrations that do not influence RAD51 binding to ssDNA. In human cells, 1 inhibits HR (IC50 13.1 ± 1.6 μM) without blocking RAD51's ability to assemble into subnuclear foci at sites of DNA damage. We determined that the active constituent of 1 is actually an oxidized derivative (termed RI(dl)-1 or 8) of the original screening compound. Our SAR campaign also yielded RI(dl)-2 (hereafter termed 9h), which effectively blocks RAD51's D-loop activity in biochemical systems (IC50 11.1 ± 1.3 μM) and inhibits HR activity in human cells (IC50 3.0 ± 1.8 μM).

Original languageEnglish (US)
Pages (from-to)4511-4525
Number of pages15
JournalJournal of medicinal chemistry
Issue number10
StatePublished - May 26 2016

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51'. Together they form a unique fingerprint.

Cite this